{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:11:11Z","timestamp":1788898271709,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10557-018-6800-3","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:03:01Z","timestamp":1527724981000},"page":"273-280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Statin Utilization Patterns and Outcomes for Patients with Acute Coronary Syndrome During and Following Inpatient Admissions"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-5533","authenticated-orcid":false,"given":"Susan H.","family":"Boklage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Malangone-Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Lopez-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Elassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"issue":"10","key":"6800_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.4065\/84.10.917","volume":"84","author":"A Kumar","year":"2009","unstructured":"Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009;84(10):917\u201338.","journal-title":"Mayo Clin Proc"},{"issue":"2 Suppl","key":"6800_CR2","first-page":"S36","volume":"15","author":"DM Kolansky","year":"2009","unstructured":"Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am J Manag Care. 2009;15(2 Suppl):S36\u201341.","journal-title":"Am J Manag Care"},{"issue":"4","key":"6800_CR3","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1161\/CIR.0000000000000350","volume":"133","author":"D Mozaffarian","year":"2016","unstructured":"Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke Statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133(4):e38\u2013360.","journal-title":"Circulation"},{"issue":"12","key":"6800_CR4","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/clc.20356","volume":"31","author":"AA Motivala","year":"2008","unstructured":"Motivala AA, Tamhane U, Ramanath VS, Saab F, Montgomery DG, Fang J, et al. A prior myocardial infarction: how does it affect management and outcomes in recurrent acute coronary syndromes? Clin Cardiol. 2008;31(12):590\u20136.","journal-title":"Clin Cardiol"},{"key":"6800_CR5","doi-asserted-by":"crossref","unstructured":"Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 2009;54(25):2358\u20132362.","DOI":"10.1016\/j.jacc.2009.10.005"},{"issue":"11 Suppl","key":"6800_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0735-1097(17)33448-4","volume":"69","author":"AM Navar","year":"2017","unstructured":"Navar AM, Steen DL, Wojdyla D, Sanchez RJ, Khan I, Peterson E, et al. Recurrent cardiovascular event rates in a contemporary cohort of 829,498 adults with atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2017;69(11 Suppl):59.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"6800_CR7","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504.","journal-title":"N Engl J Med"},{"key":"6800_CR8","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390.","DOI":"10.1016\/S0140-6736(12)60367-5"},{"issue":"25","key":"6800_CR9","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"2","key":"6800_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1067\/mhj.2001.116959","volume":"142","author":"MA Blazing","year":"2001","unstructured":"Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. The A-to-Z trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb\/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J. 2001;142(2):211\u20137.","journal-title":"Am Heart J"},{"issue":"9326","key":"6800_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7\u201322.","journal-title":"Lancet"},{"issue":"9346","key":"6800_CR12","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623\u201330.","journal-title":"Lancet"},{"issue":"25 Pt B","key":"6800_CR13","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889\u2013934.","journal-title":"J Am Coll Cardiol"},{"key":"6800_CR14","doi-asserted-by":"crossref","unstructured":"Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227\u2013239.","DOI":"10.1161\/01.CIR.0000133317.49796.0E"},{"issue":"1","key":"6800_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s13300-015-0148-5","volume":"7","author":"L Montejano","year":"2016","unstructured":"Montejano L, Vo L, McMorrow D. Transitions of care for people with type 2 diabetes: utilization of antihyperglycemic agents pre- and post-hospitalization. Diabetes Ther. 2016;7(1):91\u2013103.","journal-title":"Diabetes Ther"},{"issue":"2","key":"6800_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2014full report. J Clin Lipidol. 2015;9(2):129\u201369.","journal-title":"J Clin Lipidol"},{"issue":"39","key":"6800_CR17","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999\u20133058.","journal-title":"Eur Heart J"},{"issue":"25","key":"6800_CR18","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","author":"National Cholesterol Education Program Expert Panel on Detection","year":"2002","unstructured":"National Cholesterol Education Program Expert Panel on Detection. Evaluation and treatment of high blood cholesterol in adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143\u2013421.","journal-title":"Circulation"},{"issue":"13","key":"6800_CR19","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711\u20138.","journal-title":"JAMA"},{"issue":"6","key":"6800_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.18553\/jmcp.2016.22.6.685","volume":"22","author":"I Lin","year":"2016","unstructured":"Lin I, Sung J, Sanchez RJ, Mallya UG, Friedman M, Panaccio M, et al. Patterns of statin use in a real-world population of patients at high cardiovascular risk. J Manag Care Spec Pharm. 2016;22(6):685\u201398.","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"6800_CR21","first-page":"434","volume":"9","author":"Q Huang","year":"2016","unstructured":"Huang Q, Grabner M, Sanchez RJ, Willey VJ, Cziraky MJ, Palli SR, et al. Clinical characteristics and unmet need among patients with atherosclerotic cardiovascular disease stratified by statin use. Am Health Drug Benefits. 2016;9(8):434\u201344.","journal-title":"Am Health Drug Benefits"},{"issue":"8","key":"6800_CR22","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","volume":"2","author":"LD Colantonio","year":"2017","unstructured":"Colantonio LD, Huang L, Monda KL, Bittner V, Serban MC, Taylor B, et al. Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries. JAMA Cardiol. 2017;2(8):890\u20135.","journal-title":"JAMA Cardiol"},{"issue":"3","key":"6800_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/clc.22641","volume":"40","author":"DL Steen","year":"2017","unstructured":"Steen DL, Khan I, Becker L, Foody JM, Gorcyca K, Sanchez RJ, et al. Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and\/or diabetes mellitus in 2014: insights from a large US managed-care population. Clin Cardiol. 2017;40(3):155\u201362.","journal-title":"Clin Cardiol"},{"issue":"22","key":"6800_CR24","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1016\/j.jacc.2017.03.585","volume":"69","author":"RS Rosenson","year":"2017","unstructured":"Rosenson RS, Farkouh ME, Mefford M, Bittner V, Brown TM, Taylor B, et al. Trends in use of high-intensity statin therapy after myocardial infarction, 2011 to 2014. J Am Coll Cardiol. 2017;69(22):2696\u2013706.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"6800_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004332","volume":"6","author":"A Eisen","year":"2017","unstructured":"Eisen A, Cannon CP, Braunwald E, Steen DL, Zhou J, Goodrich EL, et al. Predictors of nonuse of a high-potency statin after an acute coronary syndrome: insights from the stabilization of plaques using Darapladib-thrombolysis in myocardial infarction 52 (SOLID-TIMI 52) trial. J Am Heart Assoc. 2017;6(1):e004332.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"6800_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","volume":"65","author":"RS Rosenson","year":"2015","unstructured":"Rosenson RS, Kent ST, Brown TM, Farkouh ME, Levitan EB, Yun H, et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015;65(3):270\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"6800_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ahj.2016.07.024","volume":"181","author":"M Valentino","year":"2016","unstructured":"Valentino M, Al Danaf J, Panakos A, Ragupathi L, Duffy D, Whellan D. Impact of the 2013 American College of Cardiology\/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke. Am Heart J. 2016;181:130\u20136.","journal-title":"Am Heart J"},{"issue":"11","key":"6800_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/clc.22343","volume":"37","author":"SS Virani","year":"2014","unstructured":"Virani SS, Woodard LD, Akeroyd JM, Ramsey DJ, Ballantyne CM, Petersen LA. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology\/American Heart Association cholesterol management guidelines. Clin Cardiol. 2014;37(11):653\u20139.","journal-title":"Clin Cardiol"},{"key":"6800_CR29","doi-asserted-by":"crossref","unstructured":"Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the Management of Atherosclerotic Cardiovascular Disease Risk A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92\u2013125.","DOI":"10.1016\/j.jacc.2016.03.519"},{"key":"6800_CR30","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","volume":"39","author":"U Landmesser","year":"2017","unstructured":"Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Boren J, et al. 2017 update of ESC\/EAS task force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2017;39:1131\u201343.","journal-title":"Eur Heart J"},{"key":"6800_CR31","unstructured":"Steg P. Cardiovascular outcomes with alirocumab after acute coronary syndrome: results of the ODYSSEY outcomes trial. Presented at the 67th Annual Scientific Session of the Am Coll Cardiol (ACC), 10\u201312 March 2018 (Presentation number 401\u201308). Orlando; 2018."},{"issue":"4","key":"6800_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.000995","volume":"3","author":"S Khera","year":"2014","unstructured":"Khera S, Kolte D, Aronow WS, Palaniswamy C, Subramanian KS, Hashim T, et al. Non-ST-elevation myocardial infarction in the United States: contemporary trends in incidence, utilization of the early invasive strategy, and in-hospital outcomes. J Am Heart Assoc. 2014;3(4):e000995.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"6800_CR33","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ahj.2008.07.030","volume":"156","author":"WJ Rogers","year":"2008","unstructured":"Rogers WJ, Frederick PD, Stoehr E, Canto JG, Ornato JP, Gibson CM, et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of myocardial infarction from 1990 to 2006. Am Heart J. 2008;156(6):1026\u201334.","journal-title":"Am Heart J"},{"issue":"4","key":"6800_CR34","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ahj.2013.12.019","volume":"167","author":"B Shah","year":"2014","unstructured":"Shah B, Bangalore S, Gianos E, Liang L, Peacock WF, Fonarow GC, et al. Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction. Am Heart J. 2014;167(4):480\u20138 e1.","journal-title":"Am Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-018-6800-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-018-6800-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T21:37:07Z","timestamp":1559252227000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-018-6800-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["6800"],"URL":"https:\/\/doi.org\/10.1007\/s10557-018-6800-3","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,31]]},"assertion":[{"value":"31 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Ms. Boklage is an employee of and stockholder in Regeneron Pharmaceuticals, Inc. Dr. Elassal was an employee of and stockholder in Regeneron Pharmaceuticals, Inc. at the time the study was conducted. Dr. Ding, Ms. Malangone-Monaco, Ms. Lopez-Gonzalez, and Ms. Henriques are employees of Truven Health Analytics, an IBM company, which was provided funding to conduct this study on behalf of Regeneron Pharmaceuticals, Inc. and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}